Flavor of the week: antibiotics

Share this article:

AstraZeneca and Roche each entered collaborations to take on hospital infections.

As noted by PMLive, AstraZeneca's collaboration with the Agency for Science, Technology and Research to attack gram-negative infections appears somewhat at odds with the drugmaker's decision to scale back its infection R&D.

Roche announced Monday that it is pursuing antibiotic research with private drugmaker Polyphor, with which it will target pseudomonas aeruginosa, an infection which the companies say accounts for 10% of US hospital-acquired infections.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.